Compounded GLP-1 Drugs
16 articles on Compounded GLP-1 Drugs, written by Shotlee and medically reviewed for clinical accuracy.
Wegovy and the Wedding Dress: The Hidden Costs of Rapid Weight Loss
Prescription weight loss drugs are becoming a wedding staple, but medical experts warn of serious side effects and ethical concerns behind the trend.
9 min read
GLP-1s & Telehealth: Navigating Risks and Ensuring Safety
The booming popularity of GLP-1 medications for weight loss has coincided with a dramatic rise in telehealth services. This article delves into the benefits and significant risks of obtaining these powerful drugs online, highlighting critical safety concerns and offering guidance for patients.
6 min read
Ozempic, Mounjaro & Compounded GLP-1s: South Africa's Regulatory Crackdown
South Africa's regulatory bodies are taking decisive action against the booming market for compounded GLP-1 weight-loss drugs, including versions of Ozempic and Mounjaro. This crackdown highlights significant safety concerns and potential risks to public health.
8 min read
GLP-1 Safety: FDA Action, TrumpRx Access & Weight Loss Drug Risks
Explore the critical safety differences between compounded GLP-1 medications and FDA-approved treatments. Understand the role of new access programs in combating unsafe alternatives.
9 min read
RFK Jr.'s Peptide Policy Could Boost Hims & Hers GLP-1 Shift
Shares of Hims & Hers surged after HHS Secretary RFK Jr. revealed FDA plans to review peptides for compounding under the 503A bulk list. This comes as the telehealth leader evolves its high-margin compounded GLP-1 business toward branded options and new peptide therapies. CEO Andrew Dudum and CMO Dr. Patrick Carroll highlight the potential for regulated, physician-led peptide access.
6 min read
Time for Guardrails on GLP-1 Compounding: Safety Risks Exposed
America faces a crisis in unregulated compounded GLP-1 drugs, with FDA reporting 1,150 adverse events including hospitalizations and deaths. Exploiting shortages of semaglutide and tirzepatide, compounders flood the market with untested products, misleading consumers. Now, with the SAFE Drugs Act and FDA crackdowns, it's time to restore safety standards.
4 min read
Hims & Hers Surges After RFK Jr. Pushes Peptide Access on Joe Rogan
Hims & Hers shares surged Monday after HHS Secretary Robert F. Kennedy Jr. expressed urgency on the Joe Rogan Experience to make 14 peptides more accessible. He highlighted FDA's review of the science behind these GLP-1 active ingredients for diabetes and weight loss. This could signal easing regulatory headwinds for telehealth providers like Hims.
5 min read
Eli Lilly Warns of Counterfeit Mounjaro, Zepbound Risks from Impurities
Eli Lilly, maker of Mounjaro and Zepbound, has discovered critical impurities in counterfeit tirzepatide versions mixed with vitamin B12. These compounded drugs pose unknown risks due to chemical reactions and lack of FDA oversight. With one in eight Americans using GLP-1s, experts urge sticking to approved medications.
5 min read
Hims & Hers, Novo Nordisk End Lawsuit, Collaborate on Wegovy Sales
In a surprise turn, Novo Nordisk is dropping its lawsuit against Hims & Hers Health, paving the way for branded Wegovy and Ozempic sales on the telehealth platform. This follows Hims' brief plan for cheaper compounded versions and FDA warnings on shortages. Patients gain better access to approved GLP-1 medications.
5 min read
NC Poison Control Warns GLP-1 Users to Use Caution
North Carolina Poison Control is alerting GLP-1 users to watch for common dosing mistakes after averaging one to two calls daily last year. With 80% involving administration errors for drugs like Ozempic, Wegovy, and Mounjaro, most cases were mild but highlight real risks. Discover symptoms, prevention strategies, and FDA advice on compounded GLP-1 drugs.
5 min read
Knockoff GLP-1 Market Still the Wild West After Hims Fiasco
Telehealth giant Hims & Hers stirred controversy by launching a cheap compounded version of Novo Nordisk's Wegovy pill, only to yank it days later amid FDA crackdowns and lawsuits. This incident highlights the ongoing Wild West in the knockoff GLP-1 market, where unapproved compounded drugs flood the scene despite resolved shortages. Patients risk ineffective or unsafe products—here's what you need to know.
5 min read
Knockoff GLP-1 Market Still the Wild West: Hims Fallout
Telehealth firm Hims & Hers sparked chaos by launching a cheap compounded Wegovy pill, only to yank it days later amid FDA crackdowns and a Novo Nordisk lawsuit. This incident highlights the ongoing Wild West in the knockoff GLP-1 market. Despite resolved shortages for Wegovy and Zepbound, unregulated compounded drugs remain widely available.
5 min read
Novo Nordisk Sues Hims & Hers Over Semaglutide Patent
Novo Nordisk has filed a lawsuit against Hims & Hers Health Inc., accusing the telehealth company of breaching its U.S. patent on semaglutide used in blockbuster obesity drugs like Ozempic and Wegovy. Despite Hims scrapping plans for a copycat Wegovy pill, Novo claims the compounded versions remain dangerous and infringing. This legal battle highlights growing tensions over compounded GLP-1 drugs post-shortage.
5 min read
Hims & Hers Shares Sink 16% as FDA Halts Wegovy Copycat Pill
Hims & Hers Health Inc. (HIMS) has halted sales of its copycat Wegovy weight loss pill just two days after launch, leading to a 16% plunge in shares amid FDA warnings and Novo Nordisk threats. This marks a regulatory pivot as GLP-1 shortages ease. Patients and investors should note the growing scrutiny on compounded versions of popular drugs like Wegovy.
5 min read
HIMS Shares Sink After FDA Vows Swift Action on Copycat GLP-1 Drugs
Hims & Hers Health's bold launch of a $49-per-month copycat GLP-1 pill to rival Wegovy's $149 price tag backfired spectacularly. FDA Commissioner Marty Makary vowed 'swift action' against such unapproved drugs, sending HIMS shares down 7.5% in premarket trading. This regulatory showdown highlights growing tensions in the GLP-1 market dominated by Novo Nordisk and Eli Lilly.
4 min read
GLP-1 Weight Loss Drugs: Understanding Safety & Pharmacy Practices
Recent news highlights the importance of safe pharmacy practices in the production of GLP-1 weight loss drugs. Understand the regulations, potential risks, and how to ensure you're getting safe and effective medication.
3 min read